🇺🇸 FDA
Pipeline program

TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, placebo capsule G065, placebo capsule G040, JNJ-61186372, JNJ-73841937, JNJ-73841937-ZCY Placebo Oral Film-Coated Tablet

73841937NSC3003

Phase 3 small_molecule active

Quick answer

TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, placebo capsule G065, placebo capsule G040, JNJ-61186372, JNJ-73841937, JNJ-73841937-ZCY Placebo Oral Film-Coated Tablet for EGFR-mutated locally advanced or metastatic Non Small Cell Lung Cancer is a Phase 3 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Janssen-Cilag International N.V.
Indication
EGFR-mutated locally advanced or metastatic Non Small Cell Lung Cancer
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials